Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 positive by licensed diagnostic test~* aged \>16 years of age (or minimum age as determined by local regulations or as legal requirements dictate)~* 50 \< cluster of differentiation (CD)4 \<500 cells/µL~* No prior AIDS-defining illness, using the Center for Diseases Control 1993 Case Definition (except pulmonary tuberculosis)~* HIV RNA ≥1000 copies/mL~* no prior exposure to antiretroviral therapy (ART) (including short course ART for preventing MTCT)~* calculated creatinine clearance (CLCr) more than or equal to 50 mL/min (Cockcroft-Gault formula)~* provision of written informed consent.~Exclusion Criteria:~* the following laboratory values:~  * absolute neutrophil count (ANC) \<500 cells/μL~ * hemoglobin \<7.0 g/dL~ * platelet count \<50,000 cells/μL~ * alanine aminotransferase and/or aspartate aminotransferase \>5 x upper limit of normal~* pregnant women or nursing mothers~* active opportunistic or malignant disease not under adequate control~* use of immunomodulators within 30 days prior to screening~* use of any prohibited medications~* current alcohol or illicit substance use that might adversely affect study participation

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 600 milligram (mg) Efavirenz (Type: ACTIVE_COMPARATOR): Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
- 400mg Efavirenz (Type: EXPERIMENTAL): Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).

Based on this trial design, predict the completion outcome and termination type (if applicable).